Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1077-1081

  Cruciani, Mario ^a   Gatti, Giorgio ^b   Mengoli, Carlo ^c   Cazzadori, Angelo ^a   Lazzarini, Luca ^a   Miletich, Franca ^c   Graziani, Maria Stella ^a   Malena, Marina ^a   Bassetti, Dante ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

EID: 0030902241     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1077     Document Type: Article

References (28)

1. Antinori, A., R. Murri, A. Ammassari, A. De Luca, A. Linzalone, A. Cingolani, F. Damiano, G. Maiuro, J. Vecchiet, G. Scoppettuolo, E. Tamburrini, and L. Ortona. 1995. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 9:1343-1350.
2. Baldwin, D. R., D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents. In vivo observation and clinical relevance. Antimicrob. Agents Chemother. 36:1176-1180.
3. Blum, R. N., L. A. Miller, L. C. Gaggini, and D. L. Cohn. 1992. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J. Acquired Immune Defic. Syndr. 5:341-347.
4. Bozzette, S. A., D. M. Finkelstein, S. A. Spector, P. Frame, W. G. Powderly, W. He, L. Phillips, D. Craven, C. Van der Host, J. Feinenberg, and the NIAID AIDS Clinical Trials Group. 1995. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus. N. Engl. J. Med. 332:693-699.
5. Centers for Disease Control and Prevention. 1995. USPHS/IDSA guidelines for the prevention of infections in persons infected with human immunodeficiency virus: a summary. Morbid. Mortal. Weekly Rep. 44(RR-8):1-34.
6. Centers for Disease Control and Prevention. 1995. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. Morbid. Mortal. Weekly Rep. 44(RR-4):1-11.
7. Cruciani, M., E. Bertazzoni-Minelli, M. Mirandola, R. Luzzati, G. Gatti, M. Merighi, S. Vento, R. Mazzi, L. Lazzarini, M. Malena, A. Benini, A. Cazzadori, G. Piemonte, D. Bassetti, and E. Concia. 1996. Twice weekly dapsone for primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data. Clin. Microbiol. Infect. 2:30-35.
8. Cushion, M. T., D. Stanforth, M. J. Linke, and P. D. Walzer. 1985. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother. 28:796-801.
9. Fallon, J., J. Lavelle, D. Ogata-Arakaki, A. Byrne, A. Graziani, A. Morgan, M. A. Amantea, K. Ownby, M. Polis, R. T. Davey, Jr., J. A. Kovacs, H. C. Lane, H. Masur, and R. R. MacGregor. 1994. Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of Pneumocystis pneumonia. Antimicrob. Agents Chemother. 38:1580-1587.
10. Gatti, G., A. Loy, R. Casazza, F. Miletich, M. Cruciani, and D. Bassetti. 1995. Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 39:1101-1106.
11. Gatti, G., M. Merighi, J. Hossein, S. Travaini, R. Casazza, M. Karlsson, M. Cruciani, and D. Bassetti. 1996. Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 40:2743-2748.
12. Girard, P. M., R. Landman, C. Gaudebout, R. Olivares, A. G. Saimot, P. Jelazko, A. Certain, F. Bové, T. Lacompte, J. P. Coulaud, and the PRIOR Study Group. 1993. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N. Engl. J. Med. 328:1514-1520.
13. Hansen, I., H. Lykkegaard Nielson, L. Heerfordt, B. Henriksen, and S. Bertelsen. 1973. Trimethoprim in normal and pathological human lung tissue. Chemotherapy 19:221-234.
14. Ioannidis, J. P. A., J. C. Cappelleri, P. R. Skolnik, J. Lau, and H. S. Sacks. 1996. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch. Intern. Med. 156:177-188.
15. Lee, B. L., I. Medina, N. L. Benowitz, P. Jacob, C. B. Wofsy, and J. Mills. 1989. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Evidence of drug interaction. Ann. Intern. Med. 110:606-611.
16. Mallolas, J., L. Zamora, J. M. Gatell, J. M. Mirò, E. Vernet, M. E. Valls, E. Soriano, and J. G. San Miguel. 1993. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimetamine. AIDS 7:59-64.
17. Martin, M. A., P. H. Cox, K. Beck, C. M. Styer, and G. N. Beall. 1992. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch. Intern. Med. 152:523-528.
18. Mirochnick, M., M. Michaels, D. Clarke, A. Brena, A. M. Regan, and S. Pelton. 1993. Pharmacokinetics of dapsone in children. J. Pediatr. 122:806-809.
19. Opravil, M., B. Joos, and R. Luthy. 1994. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasma encephalitis. Antimicrob. Agents Chemother. 38:1197-1199.
20. Podzamczer, D., M. Santin, J. Jimenez, A. Casanova, F. Bolao, and G. R. F. Gudiol. 1993. Thrice-weekly cotrimoxazole is better than weekly dapsone pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 7:501-506.
21. Rennard, S. I., G. B. Basset, D. Lecossier, K. H. O'Donnel, P. Pinkston, P. G. Martin, and R. G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538.
22. Slavin, M. A., J. F. Hoy, K. Stewart, M. B. Pettinger, C. R. Lucas, and S. J. Kent. 1992. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 6:1169-1174.
23. Stavola, J., and G. J. Noel. 1993. Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 12:644-647.
24. Tocchetti, A., R. Tambini, A. Allegro, E. Longoni, and E. Rinaldi. 1994. Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. AIDS 8:272-274.
25. Torres, R. A., M. Barr, M. Thorn, G. Gregory, S. Kiely, E. Chanin, C. Carlo, M. Martin, and J. Thornton. 1993. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am. J. Med. 95:573-583.
26. Walzer, P. D. 1995. Pneumocystis carinii, p. 2475-2487. In G. L. Mandell, J. E. Bennett, R. Dolin (ed.). Mandell, Douglas and Bennett's principle and practice of Infectious Diseases, 4th ed. Churchill Livingstone, New York.
27. Whelton, A., A. J. Watson, and R. C. Rock. 1994. Nitrogen metabolites, p. 1513-1568. In C. A. Burtis and E. R. Aswood (ed.), Tietz textbook of clinical chemistry, 2nd ed. The W. B. Saunders Co., Philadelphia.
28. Whicher, J. T., C. P. Price, and K. Spencer. 1983. Immunonephelometric and immunoturbidimetric assays for proteins. Crit. Rev. Clin. Lab. Sci. 18:213-285.